Tenaya Therapeutics (TNYA) announced positive endorsements from each trial’s independent Data Safety and Monitoring Board, DSMB, to proceed per protocol with its two cardiovascular gene therapy clinical trials, MyPEAK-1 for TN-201 and RIDGE-1 for TN-401. Enrollment in Both Dose Cohorts of the MyPEAK-1 Phase 1b/2 Clinical Trial of TN-201 for Hypertrophic Cardiomyopathy Complete; Follow-up Data from Cohort 1 and Initial Data from Cohort 2 Expected in Fourth Quarter of 2025. First Patient Dosed in 6E13 vg/kg Cohort 2 of RIDGE-1 Phase 1b Clinical Trial of TN-401 for Arrhythmogenic Right Ventricular Cardiomyopathy. Initial Cohort 1 Data for TN-401 and Enrollment of Additional Patients in Both Dose Cohorts Planned for Fourth Quarter of 2025
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TNYA: